200 related articles for article (PubMed ID: 22781398)
1. NSC 74859 enhances doxorubicin cytotoxicity via inhibition of epithelial-mesenchymal transition in hepatocellular carcinoma cells.
Hu QD; Chen W; Yan TL; Ma T; Chen CL; Liang C; Zhang Q; Xia XF; Liu H; Zhi X; Zheng XX; Bai XL; Yu XZ; Liang TB
Cancer Lett; 2012 Dec; 325(2):207-13. PubMed ID: 22781398
[TBL] [Abstract][Full Text] [Related]
2. ARK5 promotes doxorubicin resistance in hepatocellular carcinoma via epithelial-mesenchymal transition.
Xu T; Zhang J; Chen W; Pan S; Zhi X; Wen L; Zhou Y; Chen BW; Qiu J; Zhang Y; Yang Q; Feng X; Bai X; Liang T
Cancer Lett; 2016 Jul; 377(2):140-8. PubMed ID: 27126361
[TBL] [Abstract][Full Text] [Related]
3. STAT3 cooperates with Twist to mediate epithelial-mesenchymal transition in human hepatocellular carcinoma cells.
Zhang C; Guo F; Xu G; Ma J; Shao F
Oncol Rep; 2015 Apr; 33(4):1872-82. PubMed ID: 25653024
[TBL] [Abstract][Full Text] [Related]
4. NSC 74859-mediated inhibition of STAT3 enhances the anti-proliferative activity of cetuximab in hepatocellular carcinoma.
Chen W; Shen X; Xia X; Xu G; Ma T; Bai X; Liang T
Liver Int; 2012 Jan; 32(1):70-7. PubMed ID: 22098470
[TBL] [Abstract][Full Text] [Related]
5. FBW7 increases chemosensitivity in hepatocellular carcinoma cells through suppression of epithelial-mesenchymal transition.
Yu J; Zhang W; Gao F; Liu YX; Chen ZY; Cheng LY; Xie SF; Zheng SS
Hepatobiliary Pancreat Dis Int; 2014 Apr; 13(2):184-91. PubMed ID: 24686546
[TBL] [Abstract][Full Text] [Related]
6. Ascochlorin Enhances the Sensitivity of Doxorubicin Leading to the Reversal of Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma.
Dai X; Ahn KS; Wang LZ; Kim C; Deivasigamni A; Arfuso F; Um JY; Kumar AP; Chang YC; Kumar D; Kundu GC; Magae J; Goh BC; Hui KM; Sethi G
Mol Cancer Ther; 2016 Dec; 15(12):2966-2976. PubMed ID: 27765853
[TBL] [Abstract][Full Text] [Related]
7. Runt-related transcription factor 3 reverses epithelial-mesenchymal transition in hepatocellular carcinoma.
Tanaka S; Shiraha H; Nakanishi Y; Nishina S; Matsubara M; Horiguchi S; Takaoka N; Iwamuro M; Kataoka J; Kuwaki K; Hagihara H; Toshimori J; Ohnishi H; Takaki A; Nakamura S; Nouso K; Yagi T; Yamamoto K
Int J Cancer; 2012 Dec; 131(11):2537-46. PubMed ID: 22488108
[TBL] [Abstract][Full Text] [Related]
8. CCR7 preservation via histone deacetylase inhibition promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells.
Yang L; Chang Y; Cao P
Exp Cell Res; 2018 Oct; 371(1):231-237. PubMed ID: 30107147
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of TWIST enhances the cytotoxicity of chemotherapeutic drugs in doxorubicin-resistant HepG2 cells by suppressing MDR1 and EMT.
Li R; Wu C; Liang H; Zhao Y; Lin C; Zhang X; Ye C
Int J Oncol; 2018 Oct; 53(4):1763-1773. PubMed ID: 30066890
[TBL] [Abstract][Full Text] [Related]
10. ZnAs@SiO
Huang Y; Zhou B; Luo H; Mao J; Huang Y; Zhang K; Mei C; Yan Y; Jin H; Gao J; Su Z; Pang P; Li D; Shan H
Theranostics; 2019; 9(15):4391-4408. PubMed ID: 31285768
[No Abstract] [Full Text] [Related]
11. N1-guanyl-1,7-diaminoheptane (GC7) enhances the therapeutic efficacy of doxorubicin by inhibiting activation of eukaryotic translation initiation factor 5A2 (eIF5A2) and preventing the epithelial-mesenchymal transition in hepatocellular carcinoma cells.
Lou B; Fan J; Wang K; Chen W; Zhou X; Zhang J; Lin S; Lv F; Chen Y
Exp Cell Res; 2013 Oct; 319(17):2708-17. PubMed ID: 23958463
[TBL] [Abstract][Full Text] [Related]
12. STAT3 activation mediates epithelial-to-mesenchymal transition in human hepatocellular carcinoma cells.
Zhang CH; Guo FL; Xu GL; Jia WD; Ge YS
Hepatogastroenterology; 2014 Jun; 61(132):1082-9. PubMed ID: 26158169
[TBL] [Abstract][Full Text] [Related]
13. Cx32 reverses epithelial-mesenchymal transition in doxorubicin-resistant hepatocellular carcinoma.
Yu M; Han G; Qi B; Wu X
Oncol Rep; 2017 Apr; 37(4):2121-2128. PubMed ID: 28260043
[TBL] [Abstract][Full Text] [Related]
14. Norcantharidin inhibits IL-6-induced epithelial‑mesenchymal transition via the JAK2/STAT3/TWIST signaling pathway in hepatocellular carcinoma cells.
Gao Y; Li W; Liu R; Guo Q; Li J; Bao Y; Zheng H; Jiang S; Hua B
Oncol Rep; 2017 Aug; 38(2):1224-1232. PubMed ID: 28677802
[TBL] [Abstract][Full Text] [Related]
15. Coexpression of gene Oct4 and Nanog initiates stem cell characteristics in hepatocellular carcinoma and promotes epithelial-mesenchymal transition through activation of Stat3/Snail signaling.
Yin X; Zhang BH; Zheng SS; Gao DM; Qiu SJ; Wu WZ; Ren ZG
J Hematol Oncol; 2015 Mar; 8():23. PubMed ID: 25879771
[TBL] [Abstract][Full Text] [Related]
16. linc‑ROR facilitates hepatocellular carcinoma resistance to doxorubicin by regulating TWIST1‑mediated epithelial‑mesenchymal transition.
Zhang Y; Wu W; Sun Q; Ye L; Zhou D; Wang W
Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760121
[TBL] [Abstract][Full Text] [Related]
17. Clinical implication of Frizzled 2 expression and its association with epithelial-to-mesenchymal transition in hepatocellular carcinoma.
Asano T; Yamada S; Fuchs BC; Takami H; Hayashi M; Sugimoto H; Fujii T; Tanabe KK; Kodera Y
Int J Oncol; 2017 May; 50(5):1647-1654. PubMed ID: 28350091
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin-induced epithelial-mesenchymal transition through SEMA 4A in hepatocellular carcinoma.
Pan JX; Wang F; Ye LY
Biochem Biophys Res Commun; 2016 Oct; 479(4):610-614. PubMed ID: 27697528
[TBL] [Abstract][Full Text] [Related]
19. ZEB1 mediates doxorubicin (Dox) resistance and mesenchymal characteristics of hepatocarcinoma cells.
Long L; Xiang H; Liu J; Zhang Z; Sun L
Exp Mol Pathol; 2019 Feb; 106():116-122. PubMed ID: 30615851
[TBL] [Abstract][Full Text] [Related]
20. Epithelial to mesenchymal transition is associated with shorter disease-free survival in hepatocellular carcinoma.
Yamada S; Okumura N; Wei L; Fuchs BC; Fujii T; Sugimoto H; Nomoto S; Takeda S; Tanabe KK; Kodera Y
Ann Surg Oncol; 2014 Nov; 21(12):3882-90. PubMed ID: 24833103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
